John A. Orwin - 15 Sep 2025 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
Director
Signature
/s/ Eric Loumeau, Attorney-in-Fact
Issuer symbol
ANAB
Transactions as of
15 Sep 2025
Transactions value $
$0
Form type
4
Filing time
17 Sep 2025, 16:02:23 UTC
Previous filing
19 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Orwin John A Director C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO /s/ Eric Loumeau, Attorney-in-Fact 17 Sep 2025 0001477384

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise $0 +1,300 +13.88% $0 10,665 15 Sep 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Restricted Stock Unit Options Exercise $0 -1,300 -50% $0 1,300 15 Sep 2025 Common Stock 1,300 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date.